60 Degrees Pharmaceuticals receives FDA orphan drug designation for tafenoquine to treat acute babesiosis

60 DEGREES PHARMACEUTICALS, INC.

FDA granted orphan drug designation for tafenoquine for acute babesiosis; company qualifies for market exclusivity, tax credits, and exemption from certain FDA filing fees.
Company entered agreement with Tufts Medical Center for first clinical trial in human babesiosis patients; recruitment starts June 13, 2024, with at least 24 hospitalized patients.
Babesiosis is transmitted by deer ticks; up to 47,600 of ~476,000 annual Lyme patients may be co-infected with Babesia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.